@CatherineaOC @TumorBoardTues @marklewismd @MPishvaian @JohnEbbenMDPhD @EileenMOReilly @duiliorocha_onc @CowzerDarren @VParoder @CureNETs @dcmadoff @GABOUALFA @MHLars @nihardesai7 @DrKhanUmar @KristenCiombor @rcarvalhoonco @NirajGusani @BenWestphalen @carlacav @CathyEngMD @SunnieSKim @FogacciJoao @RachelRiechelm2 @HalletJulie @shafiarahman_ @oncologician @ShaalanBeg @HardingJJMD @DrAngelaLamarca @Sarbaji85064063 @jenna_k_lovely @Ja_Capdevila @cancerassassin1 @drenriquegrande @netcancerfound @curecc @CCA_Alliance @MpillaGabriel @mona_hssn @Neuroendocrine @samdoc_mamc @KGDWrites @StijnHentzen @michelle_mh2984 @kmody29 @manjuggm @benweinbergmd @DrJashDatta VHL May be an important genomic biomarker to add to this list as we now have Belzutifan available to treat these patients. Our center data presented at #ASCO2023 ascopubs.org/doi/abs/10.120… by @md_anusha

3/5 #TumorBoardTuesday Case🎀 🎥 TBT in a vide@o @RachelRiechelm2 shared key points: ✅NGS critical in NETs–change substantially over time! ✅Hypermut after CAPE/TEM more common than we think ✅Strategies that use dual IO are under active investigation- may be more effectiveRg

So excited for my first #ENETS oral presentation!! We will talk about a novel NET biomarker “hGP80” Also our work with @net_connectinfo looking at NGS practice patterns among Global NET specialists will be presented as poster. @Ja_Capdevila 🦓 #neuroendocrinetumors@UKMarkeyF

t-NET, 11 Mitosis/10HPF and Ki67 40%.Morphology intermediate: LCNEC-atypical carcinoid.TMB 23!!Pt qualifed for our immuno trial.We at @net_connectinfo studying NGS practice pattern in NETs globally. Do u use NGS for NETs/NEC? Upfront or Relapse? Trials or SOC? @pashtoonkasi